Prolactin, its physiological function and role in breast oncogenesis (a review of the literature)
Keywords:breast cancer, prolactin, prolactin receptors, hyperprolactinemia, review
AbstractBreast cancer is the most frequent cancer among women, impacting 2.1 million individuals each year, and also causes the greatest number of cancer-related deaths among women. Prolactin, known as not only a hormone involved in normal breast development and lactation, but also a cytokine, has been hypothesized to be important in the etiology of breast cancer. The literature review contains the data regarding the physiological role of prolactin, as well as its synthesis, regulation, pathogenesis, and clinical manifestations of hyperprolactinemic states. We have described the results of the relevant epidemiological trials on the role of prolactin in breast oncogenesis, particularly in different molecular types of breast cancer. The publications (reviews, original articles, results of in vitro, in vivo and clinical studies, meta-analyses) used in this work were analyzed using the search databases such as PubMed, MEDLINE, Medscape.
http://ncru.inf.ua (National Cancer Registry of Ukraine).
Frantz A.G., Kleinberg D.L. Prolactin: evidence that it is separate from growth hormone in human blood. Science. 1970. 170(3959). 745-747. DOI:10.1126/science.170.3959.745.
Татарчук Т.Ф., Гуньков С.В., Ефименко О.А. Современные подходы к диагностике и лечению гиперпролактинемии. Репродуктивная эндокринология. 2012. № 1. С. 26-44. DOI: https://doi.org/10.18370/2309-4117.2012.3.26-44.
Иловайская И.А., Марова Е.И. Биология пролактина (молекулярные формы пролактина). Акушерство и гинекология. 2000. № 6. С. 3-6.
Щепотин И.Б., Зотов А.С., Костюченко Е.А. Пролактин, его антагонисты и неопластический процесс в молочной железе. Новоутворення. 2007. С. 3-13.
Веропотвелян П.Н., Веропотвелян Н.П., Бондаренко А.А. и др. Влияние пролактина на состояние молочной железы. Медичні аспекти здоров’я жінки. 2011. № 3-1(43). С. 29-37.
Subramani R., Nandy S.B., Pedroza A.D. et al. Role of Growth Hormone in Breast Cancer. Endocrinology. 2017. Vol. 158. Issue 6. P. 1543-1555. https://doi.org/10.1210/en.2016-1928.
O’Shea J.J., Gadina М., Shreiber R.D. Cytokine Signaling in 2002: New Surprises in JAK/STAT Pathway. Cell. 2002. Vol. 109. Suppl. S. 121-131.
Watson С.J., Burdon T.G. Prolactin Signal Transduction Mechanisms in the Mammary Gland: The Role of the Jak/Stat Pathway. Reviews of reproduction. 1996. 1(1). P. 1-5
Clapp C. et al. Regulation of blood vessels by prolactin and vasoinhibins. Advances in experimental medicine and biology. 2015.Vol. 846. P. 83-95.
Булатов А.А., Мартынов А.В., Смирнова Н.Б. Биохимическая природа пролактина сыворотки крови человека. Биохимия. 1997. Т. 62. № 9. С. 1212-1220.
Ginsburg E., Alexander S., Lieber S. et al. Characterization of ductal and lobular breast carcinomas using novel prolactin receptor isoform specific antibodies. BMC Cancer. 2010. 10. 678. DOI: 10.1186/1471-2407-10-678.
Motamedi B., Rafie-Pour H.A., Khorsavi M.R. et al. Prolactin receptor as a novel prognostic biomarker for triple-negative breast cancer patients. Ann. Diag. Path. 2020. Vol. 46. 15507. https://doi.org/10.1016/j.anndiagpath.2020.151507.
Ben-Jonathan N. et al. Prolactin as an Autocrine/Paracrine Growth Factor in Human Cancer. Trands Endocrinol. Metab. 2002. Vol. 13(6). P. 245-250. https://doi.org/10.1016/S1043-2760(02)00603-3.
Clevenger C.V. et al. The Role of Prolactin in Mammary Carcinoma. Endocrine Reviews. 2003. Vol. 24. P. 1-27.
Tworoger S.S. et al. A 20-Year Prospective Study of Plasma Prolactin as a Risk Marker of Breast Cancer Development. Prevention and Epidemiology. 2013. Vol. 73(15).
Hachim I.Y. et al. Concomitant Expression of Prolactin Receptor and TGFβ Receptors in Breast Cancer: Association With Less Aggressive Phenotype and Favorable Patient Outcome. International Journal of molecular sciences. 2019. 20(7). 1640.
Hachim I.Y. et al. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome. Human Pathology. 2016. Vol. 53. P. 142-152.
Holloran S.M. Reciprocal fine-tuning of progesterone and prolactin-regulated gene expression in breast cancer cells. Molecular and Cellular Endocrinology. 2020. Vol. 511(110859).
Rasmussen L.M. et al. Prolactin and Oestrogen Synergistically Regulate Gene Expression and Proliferation of Breast Cancer Cells. Endocr. Relat. Cancer. 2010. Vol. 17(3). 809-22.
Naderi A. Prolactin-induced protein in breast cancer. Adv. Exp. Med. Biol. 2015. 846. 189-200. DOI: 10.1007/978-3-319-12114-7_8.
Baniwal S.K., Chimge N.O., Jordan V.C. et al. Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner. PLoS One. 2013. 8(6). e62361. Published 2013 Jun 3. DOI: 10.1371/journal.pone.0062361.
Naderi A., Vanneste M. Prolactin-induced protein is required for cell cycle progression in breast cancer. Neoplasia. 2014. 16(4). 329-342.e14. DOI: 10.1016/j.neo.2014.04.001.
Jablonska K., Grzegrzolka J., Podhorska-Okolow M. et al. Prolactin-induced protein as a potential therapy response marker of adjuvant chemotherapy in breast cancer patients. Am. J. Cancer Res. 2016. Vol. 6(5). P. 878-893.
Goffin V. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge. Pharmacol. Ther. 2017. Vol. 179. P. 111-126. DOI: 10.1016/j.pharmthera.2017.05.009.
Jacobson E.M., Hugo E.R., Borcherding D.C. et al. Prolactin in breast and prostate cancer: molecular and genetic perspectives. Discov. Med. 2011. Vol. 11(59). P. 315-324.
Agarwal N., Machiels J.P., Suárez C et al. Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. Oncologist. 2016. Vol. 21(5). P. 535-536. DOI:10.1634/theoncologist.2015-0502.
Kalinina T.S., Kononchuk V.V., Sidorov S.V. et al. Analysis of prolactin receptor expression in breast cancer subtypes. Biomed. Khim. 2020. Vol. 66(1). P. 89-94. DOI: 10.18097/PBMC20206601089.
Hachim I.Y., López-Ozuna V.M., Hachim M.Y. et al. Prolactin hormone exerts anti-tumorigenic effects in HER-2 overexpressing breast cancer cells through regulation of stemness. Stem. Cell. Res. 2019. Vol. 40. 101538. DOI: 10.1016/j.scr.2019.101538.
Zhou Y., Zong H., Han L. et al. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer. J. Exp. Clin. Cancer Res. 2020. Vol. 39(1). 87. DOI: 10.1186/s13046-020-01564-4.
Luciano A.A. Clinical presentation of hyperprolactinemia. J. Reprod. Med. 1999. Vol. 44. P. 1085-1090.
Molitch M.E. Prolactinomas. The Pituitary. Ed. S. Melmed. Cambridge MA: Blacwell Sci, 1995. P. 443-477.
Григорян О.Г. и др. Гиперпролактинемия в практике гинеколога: этиология, патогенез, клиника, диагностика, лечение. Проблемы репродукции. 2013. 4. C. 14-20.
Мельниченко Г.А. и др. Гиперпролактинемия у женщин и мужчин. Пособие для врачей. 2007.
Fuh G., Colosi P., Wood W.I. et al. The pole of fat cells in Prolactin synthesis. J. Biol.Chem. 1993. Vol. 268. P. 5376-5381.
Wang M. et al. Plasma prolactin and breast cancer risk: a meta- analysis. Sci. Rep. 2016. Vol. 6. 25998. DOI: 10.1038/srep25998.
Tikk K., Sookthai D., Fortner R. et al. Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study. Breast Cancer Res. 2015. Vol. 17(1). 49. DOI:10.1186/s13058-015-0563-6.
López-Ozuna V., Hachim I., Hachim M. et al. Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy. Sci Rep. 2016. 6. 30934. https://doi.org/10.1038/srep30934.
Tworoger S.S., Eliassen A.H., Sluss P. et al. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J. Clin. Oncol. 2007 Apr 20. 25(12). 1482-8. DOI: 10.1200/JCO.2006.07.6356.
Tworoger S.S., Sorensen B., Chubak J. et al. A. Effect of a 12-month randomized clinical trial of exercise on serum prolactin concentrations in postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 2007 May. 16(5). 895-9. DOI: 10.1158/1055-9965.EPI-06-0701.
Faupel-Badger J., Sherman M., Garcia-Closas M. et al. Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br. J. Cancer. 2010. 103. 097-1102. https://doi.org/10.1038/sj.bjc.6605844.
Hachim I.Y., Hachim M.Y., Lopez V.M. et al. Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer. Applied Immunohistochemistry & Molecular Morphology. 2016 Apr. 24(4). 238-245. DOI: 10.1097/pai.0000000000000178.
Copyright (c) 2020 Practical oncology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.